Articles

Indianapolis software firm RealMed acquired

Health care software firm RealMed Corp. will keep its base of operations in Indianapolis after being acquired by health information exchange provider Availity LLC of Jacksonville, Fla. Terms of the deal announced Wednesday were not disclosed.

Read More

After health reform, Lilly looking for more

The health reform debate may have ended in Congress, but Eli Lilly and Co. remains active, sponsoring a talk about the positives of the
bill—and calling for further government efforts to help pharmaceutical research and development.

Read More

Bid deadline looms for former Hilbert mansion

The 25,000-square-foot mansion once owned by Conseco Inc. founder Stephen Hilbert was listed five years
ago at $20 million—and
about half that in recent months. Now the property is being sold in a sealed-bid auction, and offers are due Friday.

Read More

California OKs Anthem rate hike after controversy

The California Department of Insurance said Wednesday it approved a rate increase averaging about 14 percent for Anthem Blue
Cross customers. The department also OK’d a nearly 19-percent increase for Blue Shield of California.

Read More

Estimate puts Indiana health overhaul costs at $3.1B

Family and Social Services Administration Secretary Anne Murphy and acting Insurance Commissioner Stephen Robertson have sent
Gov. Mitch Daniels a letter that now estimates the overhaul will cost Indiana $235 million more than the previous estimate
in May.

Read More

VA hospital, health-info exchange enter pilot project

The Roudebush Veterans Affairs Medical Center and the Indiana Health Information Exchange are going to work to make
their medical record systems talk to each other in a pilot project spearheaded by the U.S. Department of Veterans Affairs.

Read More

Lilly woes take notch out of debt rating

Even with debt levels at Eli Lilly and Co. at paltry lows, a string of bad news finally forced Standard & Poor’s
to lower
its rating on the company’s senior unsecured debt. But the New York-based agency said it believes the Indianapolis-based
drugmaker will eventually break its string of bad luck on developing new products.

Read More